Some meta-analyses and large clinical trials have shown that SGLT2 inhibitors reduce cardiovascular events in patients with type 2 diabetes and reduced the rate of hospitalization for heart failure in patients with heart failure [1–10]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.